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Abstract
Background: In periodontitis, treatment aimed at controlling the periodontal biofilm infection
results in a resolution of the clinical and histological signs of inflammation. Although the cell types
found in periodontal tissues following treatment have been well described, information on gene
expression is limited to few candidate genes. Therefore, the aim of the study was to determine the
expression profiles of immune and inflammatory genes in periodontal tissues from sites with severe
chronic periodontitis following periodontal therapy in order to identify genes involved in tissue
homeostasis.
Gingival biopsies from 12 patients with severe chronic periodontitis were taken six to eight weeks
following non-surgical periodontal therapy, and from 11 healthy controls. As internal standard,
RNA of an immortalized human keratinocyte line (HaCaT) was used. Total RNA was subjected to
gene expression profiling using a commercially available microarray system focusing on
inflammation-related genes. Post-hoc confirmation of selected genes was done by Realtime-PCR.
Results: Out of the 136 genes analyzed, the 5% most strongly expressed genes compared to
healthy controls were Interleukin-12A (IL-12A), Versican (CSPG-2), Matrixmetalloproteinase-1
(MMP-1), Down syndrome critical region protein-1 (DSCR-1), Macrophage inflammatory protein-
2β (Cxcl-3), Inhibitor of apoptosis protein-1 (BIRC-1), Cluster of differentiation antigen 38 (CD38),
Regulator of G-protein signalling-1 (RGS-1), and Finkel-Biskis-Jinkins murine osteosarcoma virus
oncogene (C-FOS); the 5% least strongly expressed genes were Receptor-interacting Serine/
Threonine Kinase-2 (RIP-2), Complement component 3 (C3), Prostaglandin-endoperoxide
synthase-2 (COX-2), Interleukin-8 (IL-8), Endothelin-1 (EDN-1), Plasminogen activator inhibitor
type-2 (PAI-2), Matrix-metalloproteinase-14 (MMP-14), and Interferon regulating factor-7 (IRF-7).
Conclusion: Gene expression profiles found in periodontal tissues following therapy indicate
activation of pathways that regulate tissue damage and repair.
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Background
Non-surgical periodontal therapy has been shown to
result in a significant reduction of pocket probing depths
and bleeding on probing, and attachment gain [1-5].
When combined with periodontal maintenance a long-
term stability of periodontal conditions, i.e. a significantly
reduced incidence of additional attachment loss and
reduction in bleeding on probing (BOP), is achievable
and has been shown even in residual pockets with prob-
ing depths of greater than 7 mm [4,6]. These clinical data
indicate that significant changes in the immune/inflam-
matory response occur following treatment. However, it is
unknown, whether the clinical signs following periodon-
tal therapy are associated with an expression profile of
inflammatory and immunological genes that is compati-
ble with periodontal health.
Despite the large amount of clinical data, changes in the
inflammatory status following non-surgical therapy have
only been sparsely studied in humans. Histological stud-
ies have indicated that the gingival infiltrate associated
with dental plaque is mainly characterized by a B cells and
plasma cells [7]. Following therapy, the density of CD19,
CD20, CD30 and CD45RO positive cells were found to be
reduced, while the overall relative number of CD3 posi-
tive cells remained unchanged [8-11]. Few studies that
have attempted to analyze the expression of inflammation
related genes following non-surgical therapy; they have
been limited to selected genes, e.g. IL-1β[12,13], IFN-γ, IL-
2, IL-4, IL-5, IL-6, and TNF-α [13]. A more comprehensive
analysis of gene expression related to immune and
inflammatory processes is, however, needed to fully
appraise the genes involved in tissues homeostasis follow-
ing therapy.
Therefore, the aim of this study was to analyze the expres-
sion profiles of a broad spectrum of genes associated to
immune or inflammatory processes in the gingiva of per-
iodontitis sites following periodontal therapy and to iden-
tify candidate genes that may serve as targets for new
treatment or diagnostic strategies.
Results
Demographics and periodontal condition
Demographics and periodontal findings of enrolled peri-
odontitis patients before and following treatment and of
healthy controls are shown in Table 1. Overall, non-surgi-
cal periodontal therapy resulted in a reduction of bleeding
on probing (BOP) from 58.6 ± 29.8 to 19.3 ± 13.4. The
percentage of sites with PPD of 4 to 6 mm was reduced
from 42.2 ± 13.8 to 30.6 ±18.9 and sites with initial PPD
of 7 mm and greater from 18.9 ± 3.9 to 15.7 ± 5.8 follow-
ing supra- and subgingival debridement.
Gene expression profiles
In gingival tissues from treated periodontitis sites, the 5%
most strongly expressed genes were Interleukin-12A (IL-
12A, NM_000882, 3.1-fold), Versican (CSPG-2,
NM_004385, 3.35-fold), Matrix metalloproteinase-1
(MMP-1, NM_002421, 3.37-fold), Down syndrome criti-
cal region protein-1 (DSCR-1, NM_004414, 3.79-fold),
Macrophage inflammatory protein-2beta (cxcl-3,
NM_002090, 3.99-fold), Inhibitor of apoptosis protein-1
(BIRC-1, NM_004536, 4.04-fold), Cluster of differentia-
tion antigen 38 (CD38, NM_001775, 4.43-fold), Regula-
tor of G-protein signalling-1 (RGS-1, NM_002922, 5.53-
fold), and Finkel-Biskis-Jinkins murine osteosarcoma
virus oncogene (C-FOS, NM_005252, 5.65-fold). The 5%
least expressed genes were Receptor-interacting serine/
threonine kinase-2 (RIP-2, NM_003821, 0.01-fold),
Complement component 3 (C3, NM_000064, 0.02-fold),
Prostaglandin-endoperoxide synthase-2 (COX-2,
NM_000963, 0.02-fold), Interleukin-8 (IL-8,
NM_000584, 0.02-fold), Endothelin-1 (EDN-1,
NM_001955, 0.03-fold), Plasminogen activator inhibitor
type-2 (PAI-2, NM_000602, 0.04-fold), Matrixmetallo-
proteinase-14 (MMP-14, NM_004995, 0.04-fold), and
Interferon regulating factor-7 (IRF-7, NM_00157, 0.05-
fold) (Figure 1, 2, 3). The expression of the described
genes was significantly different (p < 0.05) between
treated periodontitis sites and healthy controls. The
results of the Realtime-PCR are being shown in Table 2.
Compared to the housekeeping genes, the 5 analyzed
genes were up-regulated by a factor of 2.40 to 9.63.
Discussion
An important finding of the study is that in periodontitis
sites following non-surgical therapy the overall expression
profile was downregulated compared to healthy controls.
The diminished expression of inflammatory and immune
related genes may indicate that periodontal therapy
results in a strong reduction of the bacterial challenge thus
Table 1: Demographics and periodontal conditions in the study 
subjects.
Test Control
Subjects (n) 12 11
Age (years) 46.6 38.5
± SD 11.7 5.6
Females 6 7
Smokers 4 3
Mean no. of teeth/subject ± SD 22.4 ± 5.9 27.36 ± 1.4
Mean % of sites with PPD 4–6 mm ± SD 42.2 ± 13.8 0
following SGD 30.6 ± 18.9 0
Mean % of sites with PPD ≥ 7 mm ± SD 18.9 ± 3.9
following SGD 15.7 ± 5.8
Mean % of sites with BOP ± SD 58.6 ± 29.8
following SGD 19.3 ± 13.4
SD = standard deviation, SGD = subgingival debridement.BMC Medical Genomics 2008, 1:30 http://www.biomedcentral.com/1755-8794/1/30
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resulting in a decreased stimulation of inflammatory/
immune responses. In this regard the decreased expres-
sion of pro-inflammatory genes like IL-1 and IL-6 that
have been demonstrated to be over-expressed in untreated
periodontitis sites [14-16] may indicate a strong down-
regulation of the pro-inflammatory immune response
induced by periodontal treatment.
In most published microarray studies cutoffs of two to
threefold up- or down-regulation have been used to
define differential expression from controls [17]. For
interpretation of the results, we even expanded this cutoff
by focussing on the 5 percent most strongly up- or down-
regulated genes to determine candidate genes that are
associated to the regulation of tissue homeostasis follow-
ing periodontal therapy.
Among the up-regulated genes, DSCR-1 inhibits the
dephosphorylation of the nuclear factor of activated T-
cells (NFAT) by calcineurin, which leads to decreased T-
cell activation and cytokine production [18]. Moreover,
DSCR-1 down-regulates transcription of several pro-
inflammatory factors, including COX-2 and IL-8 [19,20],
which were also down-regulated following periodontal
therapy.
IL-12 is known to be mainly a product of activated inflam-
matory cells (monocytes, macrophages, neutrophils,
microglia and dendritic cells) and induces the differentia-
tion of T helper 1 (TH1) cells. The biologically active IL-12
(IL-12p70) is a heterodimeric cytokine that consists of
two heterologous chains, named p40 and p35. The up-
regulated expression of IL-12p35 found in the present
Logarithmic depiction of gene groups and genes analyzed: Chemokines & chemokine receptors, complement system, acute  phase proteins, adhesion molecules, Toll-like receptors, growth factors, and matrix-metalloproteinases Figure 1
Logarithmic depiction of gene groups and genes analyzed: Chemokines & chemokine receptors, complement 
system, acute phase proteins, adhesion molecules, Toll-like receptors, growth factors, and matrix-metallopro-
teinases. Black bars represent the 5% strongest and the 5% weakest expressed genes. Data represent relative x-fold expres-
sion compared to healthy controls.BMC Medical Genomics 2008, 1:30 http://www.biomedcentral.com/1755-8794/1/30
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study may indicate an enhanced production of IL-12 and
thus may indicate a TH1 response in the treated periodon-
tal tissues. An elevated IL-12 production has already been
described in patients following periodontal therapy
[21,22]. Also, the increased expression of CD38, which is
found on early T-cell precursors and mature T cells upon
mitogenic activation indicates a T-cell response [23].
Regulatory T-cells express high levels of Regulator of RGS-
1 upon cell activation [24]. These regulatory T-cells coun-
teract the collateral tissue damage initiated by an antimi-
crobial immune response [25]. The increased expression
of RGS-1 following therapy may be a mechanism to limit
the damage upon antigen-induced inflammation. The
increased expression of BIRC-1, a potent inhibitor of acti-
vated caspase-3 and -7 [26] and the decreased expression
of RIP-2, a strong activator of NF-κB and Fas receptor
induced apoptosis [27] further support this notion. It has
been described that in untreated periodontitis sites, the
activity of caspase-3, -7, and Fas is increased compared to
healthy tissues [28] and thus the up-regulation of BIRC-1
as well as decreased expression of RIP-2 may represent dif-
ferent protective host mechanisms to control apoptotic
processes following periodontal therapy.
C-Fos, a member of the Fos family of transcription factors,
together with Jun family members forms the group of AP-
1 proteins, which, after dimerisation, bind to promoter
and enhancer regions of target genes associated to cell
proliferation, differentiation, and apoptosis [29]. Cellular
processes that are characteristic to wound healing proc-
esses may also be seen following periodontal therapy.
CXCL-3 expression has been described to drastically
increase after inoculation of Porphyromonas gingivalis in
rats immunized against P. gingivalis [30]. IRF-7 is essential
for the induction of a systemic type-I Interferon (IFN-
alpha/beta) response for innate antiviral immunity as
well as the induction of a CD8+ T-cell response in adaptive
immunity [31]. The decreased expression of IRF-7 may
indicate a weak CD8+ T-cell response and corroborates
findings that have shown that CD8+ cytotoxic T-cell-medi-
Logarithmic depiction of gene groups and genes analyzed: Cytokines & cytokine receptors, enzymes & matrix proteins Figure 2
Logarithmic depiction of gene groups and genes analyzed: Cytokines & cytokine receptors, enzymes & matrix 
proteins. Black bars represent the 5% strongest and the 5% weakest expressed genes. Data represent relative x-fold expres-
sion compared to healthy controls.BMC Medical Genomics 2008, 1:30 http://www.biomedcentral.com/1755-8794/1/30
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ated immunity does not play a major role in periodontal
tissue destruction [32].
The finding of an increased expression of MMP-1 corrob-
orates previous findings in treated periodontal tissues
[33]. CSPG-2 is a large chondroitin sulfate proteoglycan
that has been found in periodontal tissues [34] and is
known to be involved in tissue formation by capturing a
temporal space for succeeding tissues/cells in embryonic
tissue, cell adhesion, cell proliferation and cell migration
[35]. Therefore, its increased expression fits into the con-
text of healing/restructuring processes that take place fol-
lowing non-surgical periodontal treatment.
MMP-14 was strongly down-regulated, when compared
with healthy controls. As this membrane bound protein-
ase has not been found to be over-expressed in gingival
tissues from periodontitis sites [35], the role it plays for
Logarithmic depiction of gene groups and genes analyzed: Signal transduction & transcription factors Figure 3
Logarithmic depiction of gene groups and genes analyzed: Signal transduction & transcription factors. Black 
bars represent the 5% strongest and the 5% weakest expressed genes. Data represent relative x-fold expression compared to 
healthy controls.
Table 2: Results of the Realtime-PCR analysis.
compared to NADH-dehydrogenase compared to pyruvate-dehydrogenase
RGS-1 9.03 9.63
CD38 5.45 5.81
C-FOS 5.13 5.47
DSCR-1 3.23 3.44
CSPG-2 2.40 2.57
RGS-1 = Regulator of G-protein signalling-1; CD38 = Cluster of differentiation 38; C-FOS = Finkel-Biskis-Jinkins murine osteosarcoma virus 
oncogene; DSCR-1 = Down critical region protein 1; CSPG-2 = Versican.BMC Medical Genomics 2008, 1:30 http://www.biomedcentral.com/1755-8794/1/30
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tissue homeostasis remains unclear. C3 is an acute phase
reactant whose levels become elevated in response to
acute and chronic inflammation or tissue injury [36]. The
expression of C3 is up-regulated by pro-inflammatory
cytokines such as IL-1, IL-6, IFN and TNF-α [37]. As these
cytokines were expressed within normal range in perio-
dontitis sites following periodontal therapy, the decreased
expression of C3 may further indicate a normal inflamma-
tory status that is reached following periodontal therapy.
The same interpretation can be applied to the result of
decreased expression of END-1 and PAI-2, since they are
usually up-regulated when periodontal inflammation
exists [38-40].
It should be pointed out that the results of this study are
based on a relatively low number of specimens, which
warrants cautious interpretation. Moreover, the cellular
source of the observed expression patterns is unclear and
could probably also reflect a different cellular composi-
tion of the tissues analyzed. Further in vivo and in vitro
studies are needed to fully appraise cellular pathways and
their interaction in periodontal tissues following therapy.
Conclusion
Within the limits of the present study it may be concluded
that in periodontitis sites following non-surgical perio-
dontal therapy, the overall expression profile of immune
and inflammatory genes was downregulated compared to
healthy controls. Genes that were found to be up- or
down-regulated compared to healthy controls are associ-
ated with the activation of tissue repair mechanisms and
pathways that regulate tissue damage induced by the
immune responses.
Methods
Study subjects
Twelve patients with periodontitis and eleven healthy
controls were enrolled in the study at the Department of
Periodontology, University of Muenster, Germany.
Patients were included when they had untreated severe
generalized chronic periodontitis [41] and equal to or
more than 16 natural teeth. Patients with any of the fol-
lowing conditions were excluded from the study: require-
ment for prophylactic antibiotics; intake of any drugs;
severe cardiovascular, hepatic, immune, renal, hemato-
logical, mental, inflammatory disorders other than perio-
dontal disease or any other organ disorders. Subjects in
the control group were systemically healthy and showed
no signs of periodontitis as determined by the absence of
probing depths greater than 3 mm and overt signs of gin-
gival inflammation. All enrolled subjects gave written
consent on a form approved by the Ethics Committee of
the Medical Chamber of Westfalia-Lippe and the Medical
Faculty of the Westfalian-Wilhelms-University, Muenster,
Germany (approval number: 1Vbei, T. Beikler as PI).
Periodontal therapy
All patients received oral hygiene instructions followed by
full mouth supra- and subgingival debridement and
adjunctive subgingival irrigation with 1.0% chlorhexidine
digluconate gel. Full mouth debridement was performed
in two appointments on two consecutive days and com-
pleteness of supra- and subgingival debridement, i.e., all
pathologically exposed subgingival root surfaces feeling
hard and smooth, was determined by using a fine
explorer. Following therapy, patients were asked to rinse
twice daily with 0.2% chlorhexidine digluconate solution
for 14 days [42]. The complete study design is depicted in
Figure 4.
Gingival biopsies
Six to eight weeks following full mouth debridement, gin-
gival biopsies were obtained from periodontal sites of
patients with residual pockets probing depth of 7 mm or
greater. All of the patient samples and 7 out of the 11
healthy control specimens have been obtained by the first
author. Four healthy control specimens have been
obtained by another experienced periodontist (BE, see
Acknowledgements) using the same standardized proce-
dure in obtaining the biopsies and in processing the spec-
imen. Under local anesthesia (Articain with 1:100.000
epinephrine), paracrestal incisions were made, and muco-
periosteal flaps were reflected. The excised gingival collar
was then carefully removed from the roots and the alveo-
lar process. Gingival biopsy comprised the oral gingival
epithelium, pocket epithelium, junctional epithelium,
and the interposed connective tissue (see Figure 5). In
healthy controls, gingival biopsies were taken from the
palatal area of premolars in a similar fashion, but without
reflecting a mucogingival flap. Biopsy specimens were
immediately placed into RNA-later (Qiagen Inc., Valen-
cia, CA, USA) and stored at -20°C.
Keratinocyte culture
An immortalized human keratinocyte line (HaCaT) was
used as internal standard for RNA expression. Cells were
cultured in M199 medium supplemented with 2 mM L-
Study design and timeline Figure 4
Study design and timeline. BL = Baseline, OHI = Oral 
hygiene instruction, FMD = Full mouth disinfection, R = Re-
evaluation, S = Specimen. Grey bar represents mouth rinse 
with 0.12% Chlorhexidine (b.i.d. for 2 weeks).BMC Medical Genomics 2008, 1:30 http://www.biomedcentral.com/1755-8794/1/30
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glutamine, 10% fetal calf serum, 10% horse serum and
antibiotics, and grown at 37°C in a 5% CO2 atmosphere.
They were allowed to grow to confluence and then har-
vested and subjected to RNA extraction as described
below.
RNA extraction, cDNA synthesis with labeling, and 
hybridization of microarray slides
Total RNA was isolated using RNeasy Protect Mini Kit
(Qiagen Inc., Valencia, CA, USA) according to the manu-
facturer's instructions with the following modifications:
Tissues were disrupted by a motor pestle (Novo-direct
GmbH, Kehl, Germany) and homogenized with
QIAshredder (Qiagen Inc., Valencia, CA, USA). The
remaining DNA was removed using the RNase-Free
DNase kit (Qiagen Inc., Valencia, CA, USA). Quality and
concentration of RNA was analyzed with an Agilent 2100
Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA,
USA). Microarray analysis was performed using a human
inflammation microarray (MWG Biotech, Martinsried,
Germany), which was spotted with probes for 136 genes
associated with inflammatory and immune response, 19
housekeeping genes, and five arabidopsis control oligo-
nucleotides [43].
For hybridisation, 20 μg of total RNA originating from
treated periodontitis sites and healthy gingival tissues and
the same amount of RNA from HaCAT cells were reverse
transcribed using the CyScribe First-Strand cDNA Label-
ling Kit (Amersham Inc., Piscataway, NJ, USA) according
to the manufacturer's instructions. The cDNA of gingival
tissues were labeled with Cy5 and the internal standard
cDNA from HaCaT cells with Cy3. cDNA was cleaned
using the GFX Purification kit (Amersham Inc., Piscata-
way, NJ, USA) according to the manufacturer's instruc-
tions. Microarrays (MWG Biotech, Martinsried, Germany)
were hybridized at 42°C for 24 h under constant shaking.
Probe array scanning and analysis was performed by
MWG.
Real-time-PCR
For the validation of the expression analysis real-time-
PCR of five highly expressed genes (RGS-1, CD38, C-FOS,
DSCR-1, CSPG-2) was performed. RNA was reverse tran-
scribed into cDNA using SuperScript III first-strand syn-
thesis System (Invitrogen GmbH, Karlsruhe, Germany)
according to the manufacturer's instructions. Real-time-
PCR was performed using the ABI PRISM 7700 Sequence
detection system (Applied Biosystems, Foster City, Cali-
fornia, USA) with TaqMan Primers and probes specific for
the five above mentioned genes and two additional
housekeeping genes (NADH-dehydrogenase and pyru-
vate-dehydrogenase). The reaction mixture contained 25
μl of TaqMan universal PCR master Mix, 2 μl of 10 μM of
each primer, 2.5 μl of TaqMan probe and 2 μl of cDNA. It
was adjusted to 22.5 μl with DNase/RNase free water.
Conditions of the real-time-PCR were as follows: 2.0 min
at 50°C (reverse transcription), 15 min at 95°C (RT inac-
tivation and initial activation), and then 40 cycles of
amplification for 15 sec at 95°C (denaturation), and 1
min at 60°C (annealing and extension). All heating and
cooling steps were performed with a slope of 20°C/s. A
single fluorescence reading at 530 nm was obtained for
each sample at the extension step. Samples were analyzed
in duplicates and averages were calculated for analysis of
the expression ratios using REST-software [44].
Statistics
Average expression values from treated periodontitis
biopsies were divided by expression values from healthy
gingival tissues. The 5% most strongly (3.1 to 5.65 fold)
and the 5% least strongly (0.01 to 0.05 fold) expressed
genes were identified, and Mann-Whitney ranksum tests
was performed to determine differences between treated
periodontitis sites and healthy controls.
Schematic depiction of the specimen and tissue analyzed Figure 5
Schematic depiction of the specimen and tissue ana-
lyzed.BMC Medical Genomics 2008, 1:30 http://www.biomedcentral.com/1755-8794/1/30
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